scispace - formally typeset
Open AccessJournal ArticleDOI

Interfering with SARS-CoV-2: are interferons friends or foes in COVID-19?

Ivan Zanoni
- 17 Aug 2021 - 
- Vol. 50, pp 119-127
TLDR
In this paper, the authors delineate the pathways that lead to interferon production in response to SARS-CoV-2 encounter, and elucidate how this virus hinders the production and action of these cytokines.
About
This article is published in Current Opinion in Virology.The article was published on 2021-08-17 and is currently open access. It has received 24 citations till now. The article focuses on the topics: Interferon.

read more

Citations
More filters
Journal ArticleDOI

SARS-CoV-2-specific T cells in the changing landscape of the COVID-19 pandemic

TL;DR: In this article , the authors summarized the evidence that supports the role of SARS-CoV-2-specific T cells induced by infection, by vaccination or by their combination (defined as hybrid immunity) in disease protection.
Journal ArticleDOI

Upregulated type I interferon responses in asymptomatic COVID-19 infection are associated with improved clinical outcome.

TL;DR: In this paper, the authors used a blood transcriptome approach to study biomarkers associated with differing severity of SARS-CoV-2 infection, comparing severe and mild Symptomatic disease with Asymptomatic COVID-19 and uninfected Controls.
Journal ArticleDOI

Programmed cell death: the pathways to severe COVID-19?

TL;DR: In this paper , the authors summarized the current knowledge on the role and impact of diverse programmed cell death (PCD) pathways on COVID-19 disease and identified a number of critical questions that remain to be addressed.
Journal ArticleDOI

Beyond Good and Evil: Molecular Mechanisms of Type I and III IFN Functions

TL;DR: Type I and III IFNs have overlapping roles in antiviral protection, yet the mechanisms by which they are induced and promote the expression of IFN-stimulated genes and inflammation can distinguish their biological functions.
References
More filters
Journal ArticleDOI

Dexamethasone in Hospitalized Patients with Covid-19

TL;DR: In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.
Related Papers (5)